|
|
Post by zagorgordon on Jul 24, 2014 13:38:30 GMT -5
|
|
|
|
Post by jefferson on Jul 24, 2014 13:42:50 GMT -5
Oh these guys are privy to insider info? Shit, better sell!!!
|
|
|
|
Post by BD on Jul 24, 2014 13:48:12 GMT -5
IMO, the only thing he's "privy" to is emails and phone conversations between himself and other shorts and hedgies colluding to hammer the PPS. |
|
|
|
Post by joeypotsandpans on Jul 24, 2014 14:09:32 GMT -5
I've been waiting to see when the big short would surface and it looks like it was today, this is their (ad nauseum) thesis -The letter notes how a similar product, Pfizer's Exubera, was a failure and Afrezza is even more likely to flop given strong negative warnings on its labels, including one about the potential for lung cancer. It also notes that Afrezza will be more expensive than standard insulin injections-...now you know where all the hit pieces came from. Looks like ultimate desperation at this point for the last bear raid....they went to CNBC as the final effort, sensational journalism....I would be buying with both fists here IMO.
|
|
|
|
Post by kc on Jul 24, 2014 14:37:22 GMT -5
News must be comming or they would not have driven the market down. The hedgie boys got the message. Maybe this week or next. Batten down the sails and hold on for the ride.
Long sailing ahead.
|
|
|
|
Post by orlon on Jul 24, 2014 14:50:09 GMT -5
I wasn't entirely satisfied with Matt's response. Might this not be a good time to let everyone know just who they are talking to re:partnerships?
|
|
|
|
Post by rak5555 on Jul 24, 2014 15:04:04 GMT -5
orlon - the closer they are to a deal the less likely they are to speak about it. If the negotiations have progressed to letter of intent, it is usually accompanied by a two way confidentiality agreement.
ps - I wasn't satisfied w/ matt's response either. |
|
|
|
Post by babaoriley on Jul 24, 2014 15:16:06 GMT -5
I should have posted this response on this thread, rather than the thread which included the article:
Everybody that slams MNKD by principally chronicling the Exubera story is obviously short on substance or knowledge (not to mention just plain "obviously short"). I'm hoping Matt pointed out that the insulin is quite different than Exubera in more illustrative terms than, "We think it's a much improved, next generation product," but that the author did not care to include those rebuttal comments in the article.
My guess is that a little more shorting was done by Tourbillon in the last couple of days, in anticipation of today's release. Hey, Spiro, that's how the far more clever and effective shorts get out of the mess they're in!!!
Not sure that this indicates an impending deal. Perhaps the shorts felt this one was going to trend downward slightly until a partnership announcement, better to sell short near $10, and cash in short term on the drop to $9 or less, than wait till the stock is at $9, when it might only drop .50 or so on the release of this garbage.
|
|
|
|
Post by babaoriley on Jul 24, 2014 15:17:49 GMT -5
Seems the company has underperformed the market in the last year and a half, right? How all-knowing is that? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 24, 2014 15:21:20 GMT -5
The FDA would not have approved Afrezza if it was not clearly superior in every way, i.e., efficacy AND safety, compared to Exubera or injected insulin. That is, the FDA requires a clear advantage over previous treatments before approval is granted.
|
|
|
|
Post by lynn on Jul 24, 2014 15:30:53 GMT -5
That article just reflects how our media are paid puppets . I guess the only good thing for me is my limit order I've had in place for weeks filled  I've got to stop buying this stock & just be satisfied with what I have but it sure put a smile on my face to see that I now have 333 more than I did a cpl hours ago Articles like that I just skim through so I can read the intelligent comments , I hope they did these same things to Apple & Tesla , I believe they did & that gives me confidence as we all know where they are today ! |
|
|
|
Post by seanismorris on Jul 24, 2014 15:49:57 GMT -5
I love it when this happens, come on just one more short article and we can put MNKD firmly below the 50 day average. But, this time have a more convincing argument please. Is comparing it to Exubera is all you got?
How about another hedge shorting MNKD but this time someone that actually has some focus on biotech's. Or, one with more than 20 employees, or one that doesn't have employes from another firm that basically got disbanded for insider trading.... Or, one that is more than 2 years old.
How am I supposed to buy more MNKD at $8.50 without better short arguments....
I liked the Short article on Seeking Alpha better. Their argument: because Mannkind hasn't announced a partner yet (within a few weeks after FDA approval) that means Mannkind can't find a partner at all. At least that one was more difficult to refute because it's true Mannkind doesn't have a partner yet. Never mind, we didn't really expect one yet ; )
|
|
|
|
Post by ashiwi on Jul 24, 2014 15:50:07 GMT -5
from today's release " ... Tourbillon Capital Partners wrote in a letter to investors obtained by CNBC.com. Tourbillon manages $1.2 billion and is led by former SAC Capital Advisors portfolio manager Jason Karp..."
Jason Karp used to work for SAC, Steven A Cohen's Hedge fund firm. It was the biggest short fund out there. Ultimately their dirty tactics got them in trouble with the SEC but not before Steve Cohen made many many $ billions. Apparently Jason Karp learned a lot from his former boss.
Real Scum of the earth. They will do anything for a buck.
|
|
|
|
Post by 1 percenter on Jul 24, 2014 16:17:04 GMT -5
Jason Krap is betting on the fact that Afrezza is Exubera and that MNKD's management is stupid enough to follow in the same footsteps as Pfizer. That's not a smart move if you ask me and shows he really didn't do any research at all. If he had, he would have known that MNKD isn't a one trick pony with Afrezza. We have no idea if and what any other indications Technosphere is being used or will be used in the near future. We were given a hint that the migraine indication is something that might hit soon. This is more Wall Street manipulation at its finest. I know some of you think MNKD can just hit back but they can't.
|
|
|
|
Post by bighaus89 on Jul 24, 2014 16:35:27 GMT -5
With the bear storm this past week, it seems like news could be right on the horizon. Tomorrow after hours? Monday? Either way, it is pure stock manipulation and shorts trying to drive the price down to cover.
|
|
I've got to stop buying this stock & just be satisfied with what I have but it sure put a smile on my face to see that I now have 333 more than I did a cpl hours ago 
